Resumen

MEJIA, Rossana et al. Intravenous infusion of mesenchymal stem cells for refractory systemic sclerosis management: TWo-year follow-up. Rev.Colomb.Reumatol. [online]. 2022, vol.29, n.4, pp.409-416.  Epub 22-Ago-2023. ISSN 0121-8123.  https://doi.org/10.1016/j.rcreu.2021.03.016.

Systemic sclerosis is an autoimmune disease whose etiology remains unknown. Some patients prove refractory and require other therapies. Recently, the use of mesenchymal stem cells (MSC) for the treatment of disease refractory to conventional treatments has been considered. We present a case of refractory systemic sclerosis; Wharton’s jelly mesenchymal stem cell was given in response. Decrease in perioral wrinkles, reduced telangiectasia and decrease in modified Rodnan skin score were observed two years later. A decrease in brain natriuretic peptide and improved pulmonary function were also found. And improvement of pulmonary fibrosis on high resolution tomography and capillaroscopy changes. In conclusion, MSC infusion seems to be effective and safe treatment of refractory scleroderma

Palabras clave : Scleroderma; Mesenchymal stem cell; transplantation; Scleroderma systemic; Hypertension pulmonary; Scleroderma diffuse.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )